NCT04352595

A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients

Assess Hemay808 Concentration of Different Dosage Regimen for Mild and Moderate Atopic Dermatitis Patients the Safety and Efficacy of Multicenter, Randomized, Blinded, Excipient Parallel-group Phase Ⅱ Clinical Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 148 (actual)
• Sponsor: Tianjin Hemay Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Assess Hemay808 concentration of 1%/3%/7% for treatment of mild and moderate adult atopic dermatitis patients.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	Hemay808	Hemay808 is a onitment of Hemay028, a small molecule PDE4 inhibitor.

Timeline

• Start date: 2020-04-24
• Primary completion: 2021-02-28
• Completion: 2021-04-02
• First posted: 2020-04-20
• Last updated: 2024-03-01

Locations

2 sites across 1 country: China